Infectious diseases have long been considered one of the triggers for autoimmune and autoinflammatory diseases. Since the appearance of the new coronavirus in December 2019 in the city of Wuhan, China, there have been many reports suggesting that infection with coronavirus 2 (SARS-CoV-2) precedes the appearance of several autoimmune and autoinflammatory diseases. We describe a case report of a patient who was infected with the SARS-CoV-2 virus and later developed a picture of Hashimoto’s thyroiditis.

We report a case of the use of colchicine in a patient infected with SARS-CoV-2 virus. A 37-year-old man with COVID-19 presented with moderate symptoms, mild pulmonary impairment and elevated inflammatory markers, suggesting an increased risk of cytokine storm and possible worsening of clinical condition. Experimental use of colchicine resulted in an 85% decrease in C reactive protein levels 3 days after treatment initiation and a 182.6% decrease in interleukin-6 levels 8 days after treatment initiation. Due to the lack of effective therapies, it is important to search for potential compounds and compounds that focus on controlling the danger caused by systemic inflammation in COVID-19. Although further research is needed in the area of colchicine and viral infection, preliminary efficacy was observed.

CA 72-4 is a tumor marker associated with gastrointestinal, lung and ovarian tumors. The analysis of tumor markers is not usual in COVID-19, since there is no established relationship between SARS-CoV-2 infection and the development of tumors, but data suggest that 15 percent of all human cancers worldwide may be attributed to viruses. Changes in Ca 72-4 levels were observed in individuals with COVID-19, suggesting a possible oncogenic characteristic of the virus, requiring further attention and investigation. BACKGROUND: Since the arrival of a new type of coronavirus in December 2019 in Wuhan, China, the world has undergone changes due to the pandemic impact caused by the virus. SARS-CoV-2 is mainly related to lung involvement, but gastrointestinal complaints, such as vomiting and diarrhea, have also been reported. METHODS: We brought a series of cases of patients seen in Brazil, infected by SARS-CoV-2, who had high levels of CA 72.4 during the course of the infection, suggesting a possible oncogenic characteristic of the virus under study. RESULTS: The described group showed relevant variations in the levels of the tumor marker CA 74-2 after infection by the SARS-CoV-2 virus. The minor variation of the tumor marker was 4% and the highest observed, 7146%. CONCLUSIONS: Considering that some viruses can induce the tumor process, the analysis of tumor markers after viral infection can be a useful tool in assessing the possible impact on post-pandemic global health scenario.

No abstract

In this manuscript, we hypothesize that testosterone may play a protective role against the severity of SARS-CoV-2 infection through immunomodulatory mechanisms with anti-inflammatory effects supported by the action of testosterone.